About: Concurrent Immune Suppression and Hyperinflammation in Patients With Community-Acquired Pneumonia

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Concurrent Immune Suppression and Hyperinflammation in Patients With Community-Acquired Pneumonia Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Concurrent Immune Suppression and Hyperinflammation in Patients With Community-Acquired Pneumonia
Creator	Lutter, René Van Der Poll, Tom Chousterman, Benjamin Scicluna, Brendon Brands, Xanthe Faber, Daniël Haak, Bastiaan Joost Wiersinga, W Klarenbeek, Augustijn Lariboisière, Hôpital Man, Chaoxin Otto, Natasja Yang, France
Source	Medline; PMC
abstract	BACKGROUND: The nature and timing of the host immune response during infections remain uncertain and most knowledge is derived from critically ill sepsis patients. We aimed to test the hypothesis that community-acquired pneumonia (CAP) is associated with concurrent immune suppression and systemic inflammation. METHODS: Blood was collected from 79 CAP patients within 24 h after hospitalization and 1 month after discharge; 42 age- and sex-matched subjects without acute infection served as controls. Blood leukocytes were stimulated with lipopolysaccharide (LPS) or Klebsiella pneumoniae, and cytokines were measured in supernatants. Fifteen plasma biomarkers reflective of key host response pathways were compared between CAP patients with the strongest immune suppression (lowest 25% blood leukocyte tumor necrosis factor (TNF)-α production in response to LPS) and those with the least immune suppression (highest 25% of LPS-induced TNF-α production). RESULTS: Blood leukocytes of CAP patients (relative to control subjects) showed a reduced capacity to release TNF-α, interleukin (IL)-1β, IL-6 and IL-10 upon stimulation with LPS or K. pneumoniae, with a concurrently enhanced ability to release the anti-inflammatory mediator IL-1 receptor antagonist, irrespective of the presence of sepsis (18.9% of cases). Low (relative to high) TNF-α producers displayed higher plasma levels of biomarkers reflecting systemic inflammation, neutrophil degranulation, endothelial cell activation, a disturbed vascular barrier function and coagulation activation. CONCLUSION: CAP replicates a common feature of immune suppression in sepsis. The coexistence of immune suppression and hyperinflammation in CAP argues against the theory of two distinct phases during the host response to sepsis.
has issue date	2020-05-06(xsd:dateTime)
bibo:doi	10.3389/fimmu.2020.00796
bibo:pmid	32477337
has license	cc-by
sha1sum (hex)	e2c21564edcbfe29fcced2a826404badbef89c3b
schema:url	https://doi.org/10.3389/fimmu.2020.00796
resource representing a document's title	Concurrent Immune Suppression and Hyperinflammation in Patients With Community-Acquired Pneumonia
has PubMed Central identifier	PMC7232566
has PubMed identifier	32477337
schema:publication	Front Immunol
resource representing a document's body	covid:e2c21564edcbfe29fcced2a826404badbef89c3b#body_text
is schema:about of	named entity 'sepsis' named entity 'SYSTEMIC INFLAMMATION' named entity 'CRITICALLY ILL' named entity 'IMMUNE SUPPRESSION' named entity 'NATURE' named entity 'CONCURRENT' named entity 'HOST IMMUNE RESPONSE' named entity 'hypothesis' named entity 'systemic inflammation' named entity 'concurrent' named entity 'community-acquired pneumonia' named entity 'systemic inflammation' named entity 'critically ill' named entity 'Immune Suppression' named entity 'Hyperinflammation' named entity 'K. pneumoniae' named entity 'detecting danger' named entity 'PD1' named entity 'tumor necrosis factor (TNF)-α' named entity 'BioRad' named entity 'TNF-α' named entity 'IL-10' named entity 'sputum production' named entity 'CAP' named entity 'vascular cell adhesion molecule' named entity 'COPD' named entity 'immune suppression' named entity 'Staphylococcus aureus' named entity 'LPS' named entity 'fever' named entity 'immune suppression' named entity 'plasma' named entity 'cytokines' named entity 'computed tomography scan' named entity 'community-acquired pneumonia' named entity 'leukocyte' named entity 'Vienna' named entity 'respiratory tract' named entity 'endothelial cell' named entity 'Life Technologies' named entity 'plasma levels' named entity 'plasma' named entity 'fever' named entity 'critically ill patients' named entity 'COPD' named entity 'COPD' named entity 'CAP' named entity 'lipopolysaccharide' named entity 'immune suppression' named entity 'leukocytosis' named entity 'sepsis' named entity 'TNF-α' named entity 'informed consent' named entity 'France' named entity 'TNF' named entity 'TNF-α' named entity 'LPS' named entity 'red blood cell' named entity 'CAP' named entity 'sepsis' named entity 'leukocyte' named entity 'CAP' named entity 'PSI' named entity 'MPO' named entity 'TFF3' named entity 'sepsis' named entity 'mortality rate' named entity '0.01' named entity 'control subjects'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software